This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wu, A. Articles by Rabkin, S. D. Search for Related Content PubMed PubMed Citation Articles by Wu, A. Articles by Rabkin, S. D.

Biological Purging of Breast Cancer Cells Using an Attenuated Replication-competent Herpes Simplex Virus in Human Hematopoietic Stem Cell Transplantation¹

Molecular Neurosurgery Laboratory [A. W., R. L. M., S. D. R.]; Bone Marrow Transplantation Program [A. W., A. M., X. L., M. T., K. R. M.]; Departments of Neurosurgery [R. L. M., S. D. R.]; and Microbiology and Immunology [S. D. R.], Georgetown University Medical Center, Washington, DC 20007

Autologous hematopoietic stem cell transplantation after myelosuppressive chemotherapy is used for the treatment of high-risk breast cancer and other solid tumors. However, contamination of the autologous graft with tumor cells may adversely affect outcomes. Human hematopoietic bone marrow cells are resistant to herpes simplex virus type 1 (HSV-1) replication, whereas human breast cancer cells are sensitive to HSV-1 cytotoxicity. Therefore, we examined the utility of G207, a safe replication-competent multimutated HSV-1 vector, as a biological purging agent for breast cancer in the setting of stem cell transplantation. G207 infection of human bone marrow cells had no effect on the proportion or clonogenic capacity of CD34⁺ cells but did enhance the proliferation of bone marrow cells in culture and the proportion of CD14⁺ and CD38⁺ cells. On the other hand, G207 at a multiplicity of infection of 0.1 was able to purge bone marrow of contaminating human breast cancer cells. Because G207 also stimulates the proliferation of human hematopoietic cells, it overcomes a limitation of other purging methods that result in delayed reconstitution of hematopoiesis. The efficient infection of human bone marrow cells in the absence of detected toxicity suggests that HSV vectors may also prove useful for gene therapy to hematopoietic progenitor cells.

This article has been cited by other articles:

				J. C. Hu, M. J. Booth, G. Tripuraneni, D. Davies, S. A.A. Zaidi, M. Tamburo de Bella, M. J. Slade, S. B. Marley, M. Y.A. Gordon, R. S. Coffin, et al. A Novel HSV-1 Virus, JS1/34.5-/47-, Purges Contaminating Breast Cancer Cells From Bone Marrow. Clin. Cancer Res., November 15, 2006; 12(22): 6853 - 6862. [Abstract] [Full Text] [PDF]

				R. Liu, S. Varghese, and S. D. Rabkin Oncolytic Herpes Simplex Virus Vector Therapy of Breast Cancer in C3(1)/SV40 T-antigen Transgenic Mice Cancer Res., February 15, 2005; 65(4): 1532 - 1540. [Abstract] [Full Text] [PDF]

				C. M. Thirukkumaran, J. M. Luider, D. A. Stewart, T. Cheng, S. M. Lupichuk, M. J. Nodwell, J. A. Russell, I. A. Auer, and D. G. Morris Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation Blood, July 1, 2003; 102(1): 377 - 387. [Abstract] [Full Text] [PDF]